NCT05916313 - A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

February 23, 2026

Study Completion Date

March 30, 2026

Conditions

Glioma

Interventions

DRUG

BI 764532

Trial Locations (12)

1101

RECRUITING

University Hospital of Lausanne, Lausanne

5020

RECRUITING

Salzburg Cancer Research Institute, Salzburg

8901

RECRUITING

University Hosp. Zurich, Zurich

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

37203

RECRUITING

SCRI Oncology Partners, Nashville

60528

RECRUITING

Universitätsklinikum Frankfurt, Frankfurt am Main

72076

NOT_YET_RECRUITING

Universitätsklinikum Tübingen, Tübingen

81377

RECRUITING

Klinikum der Universität München AÖR, München

92868

RECRUITING

University of California Irvine, Orange

3015 GD

RECRUITING

Erasmus Medisch Centrum-ROTTERDAM-50697, Rotterdam

08003

RECRUITING

Hospital del Mar, Barcelona

CH-5001

RECRUITING

Cantonal Hospital of Aarau, Aarau